EspeRare CEO: Proceeds From Dermelix Co-Development Pact To Fund Genetic Pre-Natal Pipeline R&D

03 Apr 2019

• By Sten Stovall

The CEO of Swiss not-for-profit foundation EspeRare tells Scrip how she will use funds generated from a co-development pact with Dermelix Biotherapeutics to create novel in utero treatments for rare genetic diseases.

Small shoes for the unborn baby in the belly of pregnant woman — DMX-101 has the potential to correct a genetic disease before birth • Source: Shutterstock

A pact with Dermelix Biotherapeutics to co-develop a cure for a rare pediatric genetic disease promises to generate vital funds for advancing EspeRare’s venture philanthropic model to tackle unmet life-threatening medical needs affecting children, the non-profit foundation’s CEO told Scrip.

Caroline Kant made the comments during an interview outlining EspeRare's pact with privately held Dermelix for co-development of the Swiss...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

06 Jun 2025

• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

04 Jun 2025

• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.